BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lipman ZM, Yosipovitch G. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. Expert Opin Pharmacother 2021;22:549-55. [PMID: 33190563 DOI: 10.1080/14656566.2020.1849142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Dalefield ML, Scouller B, Bibi R, Kivell BM. The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies. Front Pharmacol 2022;13:837671. [DOI: 10.3389/fphar.2022.837671] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Aldrich JV, McLaughlin JP. Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development. Handb Exp Pharmacol 2022;271:197-220. [PMID: 34463847 DOI: 10.1007/164_2021_519] [Reference Citation Analysis]
3 Lipman ZM, Labib A, Yosipovitch G. Current Clinical Options for the Management of Itch in Atopic Dermatitis. Clin Cosmet Investig Dermatol 2021;14:959-69. [PMID: 34377004 DOI: 10.2147/CCID.S289716] [Reference Citation Analysis]
4 Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G, Mattellone A, Tolomelli A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front Mol Biosci 2021;8:697586. [PMID: 34195230 DOI: 10.3389/fmolb.2021.697586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lipman ZM, Ingrasci G, Yosipovitch G. Approach to the Patient with Chronic Pruritus. Med Clin North Am 2021;105:699-721. [PMID: 34059246 DOI: 10.1016/j.mcna.2021.04.007] [Reference Citation Analysis]